Gilead Sciences has tagged along on Kyverna Therapeutics’ journey as a startup since the beginning, and, now, the Big Pharma has helped stock up the cell therapy biotech in an $85 million financing round to prepare for a launch into the clinic this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,